SynAct Pharma AB (OSTO:SYNACT) Total Liabilities: kr44.13 Mil (As of Mar. 2026)


OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
19 GF Score
Price kr18.92
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Total Liabilities?

SynAct Pharma AB OSTO:SYNACT +2.16% 19 Total Liabilities is kr44.13 Mil as of Mar. 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

SynAct Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr44.13 Mil.

SynAct Pharma AB's quarterly Total Liabilities declined from Sep. 2025 (kr58.76 Mil) to Dec. 2025 (kr50.23 Mil) and declined from Dec. 2025 (kr50.23 Mil) to Mar. 2026 (kr44.13 Mil).

SynAct Pharma AB's annual Total Liabilities increased from Dec. 2023 (kr51.83 Mil) to Dec. 2024 (kr56.35 Mil) but then declined from Dec. 2024 (kr56.35 Mil) to Dec. 2025 (kr50.23 Mil).

SynAct Pharma AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB Total Liabilities Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.50 16.08 51.83 56.35 50.23

SynAct Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.04 47.18 58.76 50.23 44.13
OSTO:SYNACT
19GF Score
SynAct Pharma AB OSTO:SYNACT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SynAct Pharma AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=24.093+(0.595+25.539
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=50.23

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=220.518-170.291
=50.23

SynAct Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=17.574+(0.435+26.125
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=44.13

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=237.88-193.746
=44.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr44.13 Mil mean?
SynAct Pharma AB (OSTO:SYNACT) has a Total Liabilities of kr44.13 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's Total Liabilities too high?
SynAct Pharma AB's current Total Liabilities is kr44.13 Mil. Overall, SynAct Pharma AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Total Liabilities compare to VRTX and REGN?
SynAct Pharma AB's Total Liabilities of kr44.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for SynAct Pharma AB and its competitors. SynAct Pharma AB's current Total Liabilities is kr44.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current Total Liabilities of kr44.13 Mil. The current Total Liabilities is kr44.13 Mil. SynAct Pharma AB's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current Total Liabilities is kr44.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
19GF Score

Get the complete analysis for OSTO:SYNACT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.92
Price